To include your compound in the COVID-19 Resource Center, submit it here.

Morphic raises $51.5M for oral integrin inhibitors

Morphic Therapeutic (Waltham, Mass.) raised $51.5 million in a series A round co-led by SR One and Pfizer Venture Investments.

Read the full 203 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE